Reverse stock split is a routine capital structure adjustment typically used to regain compliance with NYSE American minimum bid price requirements. Monitor for any future NYSE American compliance notice or subsequent equity offering that may follow the split.
Price Chart
Executive Summary
Apimeds Pharmaceuticals US, Inc. filed a Certificate of Amendment to effect a 1-for-10 reverse stock split, effective July 24, 2026. The split reduced outstanding shares from 15,091,180 to 1,509,118 (plus 33,506 rounding shares) and lowered par value from $0.01 to $0.001 per share. This is a routine capital structure adjustment with no direct financial impact.
Key Facts
- 1-for-10 reverse stock split effective July 24, 2026
- Outstanding shares reduced from 15,091,180 to 1,509,118 (plus 33,506 rounding shares)
- Par value reduced from $0.01 to $0.001 per share
- Authorized shares unchanged at 100,000,000 common and 10,000,000 preferred
- Stockholder approval obtained December 1, 2025 via written consent
- CUSIP changed to 03771D201
Financial Impact
No financial impact; reverse stock split is a mechanical share consolidation with no change to aggregate market cap or enterprise value.
Risk Factors
- Reverse splits often signal a low stock price and potential delisting risk if the price does not hold above the exchange minimum
- Post-split share count reduction may increase volatility and reduce liquidity
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-102321 |
| Document: 0001213900-26-102321-index-headers.html | 0001213900-26-102321 |
| Document: 0001213900-26-102321-index.html | 0001213900-26-102321 |
| Document: 0001213900-26-102321.txt | 0001213900-26-102321 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | Press Release | $4.62 | awaiting T+60 | — | $2.89 (−37.34%) |
Oct 13, 2026 13d ago | 8-K | $4.62 | awaiting T+60 | — | $2.89 (−37.34%) |
Oct 1, 2026 25d ago | 8-K | $4.10 | awaiting T+60 | — | $2.89 (−29.39%) |
Sep 22, 2026 4w ago | 8-K | $2.29 | awaiting T+60 | — | $2.89 (+26.42%) |
Aug 21, 2026 9w ago | 8-K | $4.75 | awaiting T+60 | — | $2.89 (−39.05%) |
Aug 6, 2026 11w ago | 8-K | $4.23 | awaiting T+60 | — | $2.89 (−31.56%) |
May 5, 2026 24w ago | 8-K | $30.00 $4.92 | ▼ −83.60% | ▼ −86.34% | $2.89 (−90.35%) |
May 4, 2026 25w ago | 8-K | $1.88 $5.75 | ▼ −205.85% | ▼ −203.99% | $2.89 (−53.99%) |
Apr 16, 2026 27w ago | 8-K | $1.88 $0.7324 | ▲ +61.04% | ▲ +67.19% | $2.89 (−53.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers